Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elzasonan + sertraline
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of **elzasonan** (also known as CP-448,187) and **sertraline**. Elzasonan is an investigational small-molecule drug developed as a selective antagonist of serotonin 5-HT1B and 5-HT1D receptors, developed by Pfizer. Sertraline is an established selective serotonin reuptake inhibitor (SSRI) widely used in treating depression and other mood disorders. This combination has been evaluated in clinical trials for potential enhanced antidepressant efficacy in major depressive disorder compared to sertraline (Zoloft) monotherapy. The rationale is that elzasonan's serotonin receptor antagonism may augment the serotonergic effects of sertraline, based on mechanisms involving presynaptic serotonergic modulation[1].
- Brand names
- Zoloft
- Other names
- sertralineelzasonan
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)DAT (Dopamine plasma membrane transport protein)ADRA1A (α1A)
Beyond the preview
Go deeper on elzasonan + sertraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elzasonan + sertraline.